Measles is still finding new ways to spread, with recent outbreak reporting showing tens of thousands of suspected cases in the Americas and multiple clusters emerging across the Eastern Mediterranean in 2024. The same dataset also hides a sharper edge: just 5 to 10 percentage points of vaccine coverage gap can be enough to restart transmission, even when communities look close to the herd immunity target. We pull together the key risk, coverage, diagnostic, and cost figures behind those outbreaks to explain why measles continues to surge when conditions line up.
Key Takeaways
- Measles can cause hearing loss in about 1 in 1,000 cases (risk per case).
- In a Cochrane review, vitamin A supplementation reduced measles mortality with a relative risk of about 0.48 (vitamin A relative mortality effect).
- A large Danish cohort study found that children with measles had a 2.6-fold higher risk of death from infections compared with uninfected children (multiplier risk).
- WHO reported that measles can cause long-term economic and social burden due to complications and lost productivity, with undernutrition increasing severity (measurable burden component as case severity multiplier not directly stated).
- In 2022, Global Health Expenditure measured total global health expenditure at $9.9 trillion (health spending level), affecting resources available for immunization and response (global expenditure amount).
- WHO estimated that immunization against measles, mumps, rubella (MMR) contributes to averted health costs by preventing disease; measles vaccination prevented an estimated 21.1 million deaths worldwide over 2000–2018 (estimated deaths averted).
- Measles vaccine effectiveness is about 97% against measles after 1 dose (protection probability after first dose).
- In 2023, the WHO estimated that about 66 million children remained unvaccinated for measles worldwide (number of unvaccinated children).
- In 2022, South Sudan reported MCV1 coverage of 75% (MCV1 coverage, country).
- In a study evaluating measles rapid diagnostic tests, sensitivity ranged from 70% to 95% depending on test brand and specimen type (diagnostic sensitivity range).
- In the 2024 measles outbreak summary for the Americas, 36,000+ suspected measles cases were reported during the outbreak period (suspected case count).
- In 2024 (to date), 11 measles outbreaks were reported in the WHO Eastern Mediterranean Region (number of outbreaks).
- 20% of measles cases occur in under-5 children, as reported by an analysis using global surveillance data (fraction by age group).
- The herd-immunity threshold for measles is commonly estimated at about 95% (coverage needed to stop sustained transmission).
- In a household transmission study, secondary attack rate for measles among susceptible contacts was 0.3 (30%) (secondary attack rate).
With around 66 million unvaccinated children and vaccine coverage gaps, measles outbreaks can quickly spread, causing serious complications.
Related reading
01 · Category
Clinical Outcomes3 stats
01
Measles can cause hearing loss in about 1 in 1,000 cases (risk per case).
02
In a Cochrane review, vitamin A supplementation reduced measles mortality with a relative risk of about 0.48 (vitamin A relative mortality effect).
03
A large Danish cohort study found that children with measles had a 2.6-fold higher risk of death from infections compared with uninfected children (multiplier risk).
Interpretation
Clinical Outcomes Interpretation
From a clinical outcomes perspective, measles not only leads to serious complications like hearing loss in about 1 in 1,000 cases but also increases overall infection risk substantially, with Danish data showing a 2.6-fold higher risk of death from infections, while vitamin A supplementation can cut measles mortality to about 0.48 times the risk.
02 · Category
Economic & Resource Impacts7 stats
01
WHO reported that measles can cause long-term economic and social burden due to complications and lost productivity, with undernutrition increasing severity (measurable burden component as case severity multiplier not directly stated).
02
In 2022, Global Health Expenditure measured total global health expenditure at $9.9 trillion (health spending level), affecting resources available for immunization and response (global expenditure amount).
03
WHO estimated that immunization against measles, mumps, rubella (MMR) contributes to averted health costs by preventing disease; measles vaccination prevented an estimated 21.1 million deaths worldwide over 2000–2018 (estimated deaths averted).
04
The Global Burden of Disease study estimated measles killed 139,000 people in 2019 (measles deaths, burden estimate).
05
A modeling study estimated the cost of measles outbreaks in the U.S. over 1994–1995 at $1.4 million (economic cost over a defined period).
06
The global measles vaccine market was projected to reach $3.4 billion by 2032 (forecast market amount).
07
In 2023, 1 in 5 children worldwide did not receive all basic vaccines, increasing measles outbreak risk (fraction of children missing vaccines).
Interpretation
Economic & Resource Impacts Interpretation
With measles killing about 139,000 people in 2019 and immunization linked to preventing 21.1 million deaths worldwide from 2000 to 2018, the Economic and Resource Impacts are clear that missed vaccines and undernutrition-driven severity can translate into large long-term costs and strain on limited global health spending of $9.9 trillion in 2022.
03 · Category
Vaccination Coverage5 stats
01
Measles vaccine effectiveness is about 97% against measles after 1 dose (protection probability after first dose).
02
In 2023, the WHO estimated that about 66 million children remained unvaccinated for measles worldwide (number of unvaccinated children).
03
In 2022, South Sudan reported MCV1 coverage of 75% (MCV1 coverage, country).
04
In 2022, Nigeria reported MCV1 coverage of 58% (MCV1 coverage, country).
05
In 2022, Ukraine reported MCV1 coverage of 84% (MCV1 coverage, country).
Interpretation
Vaccination Coverage Interpretation
Vaccination coverage remains uneven and too low in several countries, with MCV1 reaching only 58% in Nigeria and 75% in South Sudan in 2022 despite a 97% effectiveness after one dose and WHO estimating 66 million children were still unvaccinated worldwide in 2023.
04 · Category
Laboratory & Diagnostics1 stats
01
In a study evaluating measles rapid diagnostic tests, sensitivity ranged from 70% to 95% depending on test brand and specimen type (diagnostic sensitivity range).
Interpretation
Laboratory & Diagnostics Interpretation
In the laboratory and diagnostics context, measles rapid diagnostic tests showed wide diagnostic sensitivity variation from 70% to 95%, indicating performance can depend strongly on the specific test brand and specimen type.
05 · Category
Epidemiology Trends5 stats
01
In the 2024 measles outbreak summary for the Americas, 36,000+ suspected measles cases were reported during the outbreak period (suspected case count).
02
In 2024 (to date), 11 measles outbreaks were reported in the WHO Eastern Mediterranean Region (number of outbreaks).
03
20% of measles cases occur in under-5 children, as reported by an analysis using global surveillance data (fraction by age group).
04
95% of reported measles cases in a recent meta-analysis were linked to outbreaks (share of cases with outbreak association).
05
93% of measles patients in a recent hospital cohort had at least one complication diagnosed (complication prevalence).
Interpretation
Epidemiology Trends Interpretation
Across epidemiology trends in 2024, measles continues to spread widely with over 36,000 suspected cases reported in the Americas while 95% of cases in a meta-analysis were linked to outbreaks and 20% occurred in children under 5.
06 · Category
Transmission & Herd Immunity7 stats
01
The herd-immunity threshold for measles is commonly estimated at about 95% (coverage needed to stop sustained transmission).
02
In a household transmission study, secondary attack rate for measles among susceptible contacts was 0.3 (30%) (secondary attack rate).
03
Airborne/droplet transmission modeling for measles yields an estimated average effective infectious period of roughly 4 days (infectious period duration).
04
For measles, the incubation period is typically 10–14 days (incubation period range).
05
Measles infectiousness begins about 4 days before rash onset and continues up to about 4 days after rash onset (infectiousness window).
06
In outbreak investigations, measles contact tracing often identifies that around 20–30% of exposed contacts are susceptible (susceptible fraction among exposed).
07
Measles vaccine coverage gaps of 5–10 percentage points can be sufficient to re-enable outbreaks in modeling studies of herd immunity (coverage gap threshold).
Interpretation
Transmission & Herd Immunity Interpretation
With measles requiring about 95% herd immunity to prevent sustained spread, even small coverage gaps of 5 to 10 percentage points can reignite transmission, especially since infectiousness spans from roughly 4 days before to 4 days after rash onset.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Isabelle Moreau. (2026, February 13). Measles Outbreak Statistics. Gitnux. https://gitnux.org/measles-outbreak-statistics
MLA
Isabelle Moreau. "Measles Outbreak Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/measles-outbreak-statistics.
Chicago
Isabelle Moreau. 2026. "Measles Outbreak Statistics." Gitnux. https://gitnux.org/measles-outbreak-statistics.
Sources & references
28 datasets cited across this report · attribution is report-level
+11 additional datasets cited (not shown individually)